Immunohistochemistry analysis and chromosomal translocation abnormalities.

<p>Immunohistochemistry analysis and chromosomal translocation abnormalities.</p

Univariate and multivariate analysis for overall survival in DLBCL.

<p>Univariate and multivariate analysis for overall survival in DLBCL.</p

Histology of polyploid diffuse large B-cell lymphoma (DLBCL).

<p>(A) HE staining, large tumor cells (black arrows). (B) Tumor cells were positive for CD20. (C) HE staining, multilobated tumor cells (black arrows) with many apoptotic cells (arrow heads). (D) Tumor cells were positive for CD20. (E) HE staining, multilobated medium-sized cells (black arrows). (F) Tumor cells were positive for CD20.</p

Overall survival and progression-free survival between polyploid DLBCL, NOS (n = 45) and control DLBCL, NOS (n = 42) patients in only cases who received R-CHOP regimens.

<p>(A) The overall survival curves were significantly worse for polyploid DLBCL than control DLBCL (<i>p</i> = 0.02). (B) The progression-free survival curves were not significantly different between polyploid DLBCL and control DLBCL (<i>p</i> = 0.27).</p

Clinical outocomes and therapy of polyploid DLBCL and control DLBCL.

<p>Clinical outocomes and therapy of polyploid DLBCL and control DLBCL.</p

Clinical features of polyploid DLBCL and control DLBCL.

<p>Clinical features of polyploid DLBCL and control DLBCL.</p

Overall survival and progression-free survival between polyploid DLBCL, NOS (n = 51) and control DLBCL, NOS (n = 53) patients.

<p>(A) The overall survival curves were significantly worse for polyploid DLBCL than control DLBCL (<i>p</i> = 0.04). (B) The progression-free survival curves were not significantly different between the polyploid DLBCL and control DLBCL (<i>p</i> = 0.49).</p

Analysis of immunohistochemistry staining in polyploid DLBCL.

<p>Tumor cells were positivity in each immunohistochemistry. CD5 (X400), (B) CD10 (X400), (C) CD30 (X400), (D) BCL2 (X400), (E) BCL6 (X400) and (F) MUM1 (X400).</p

Characteristics of the soluble form of DNAM-1.

<p>(A) The soluble form of DNAM-1 (sDNAM-1) in sera from healthy volunteers (n = 38) was measured by sandwich ELISA. (B) sDNAM-1 in human serum was detected by immunoprecipitation (IP) followed by immunoblotting (IB) with mouse anti-human DNAM-1 mAb (TX25). Cell lysate of DNAM-1/ BW transfectant was used as control of membrane DNAM-1 (mDNAM-1). (C) Peripheral blood mononuclear cells (PBMCs) from healthy volunteers were stimulated with the indicated mAbs in the presence of IL-2. sDNAM-1 in the culture supernatant was measured by ELISA on day 7 after the start of culture. (D) PBMCs from healthy volunteers were stimulated with anti-CD3 and anti-DNAM-1 mAbs. On day 3 after the start of culture, the medium was replaced with fresh medium (plain) and a broad-spectrum matrix metalloproteinase (MMP) inhibitor, GM6001 (100 μM) or TAPI-1 (50 μM), was added into the culture. On day 6, sDNAM-1 in the culture supernatant was measured by ELISA. Error bars in all panels represent the mean and standard deviation (SD). * and **, <i>P</i> < 0.05 and <i>P</i> < 0.01, respectively, compared with the sDNAM-1 concentration in the culture supernatant in the presence of IL-2 alone (C) or DMSO (0.1%) alone (D).</p

Acute GVHD characteristics (univariate analysis).

<p>Acute GVHD characteristics (univariate analysis).</p